

# MODULE 4:

# Laser and surgical treatment

## EAGLE ALLIANCE





# Acknowledgement

Our sincere thanks to the **EAGLE Faculty** for developing the modules, and to the **APGS Review Experts** for their contributions throughout the review and approval process. Their guidance and dedication have been essential in ensuring the accuracy, clarity, and relevance of these educational resources.

## EAGLE Alliance Faculty – Module 4

- **Chair:** Prof. Tina Wong (Singapore)
- Assoc Prof. Shamira Perera (Singapore)
- Assoc. Prof. Visanee Tantisevi (Thailand)
- Assoc Prof. Virna Dwi Oktariana Asrory (Indonesia)

## APGS Expert Review – Module 4

- Dr. Seng Kheong Fang (Malaysia)
- Prof. Tanuj Dada (India)



# Introduction to the **EAGLE Alliance Initiative**

## Welcome to the **EAGLE Alliance initiative:**

The EAGLE Alliance has been developed to strengthen clinical capacity in glaucoma management among general ophthalmologists across Asia. Through expert-led modules aligned with the APGG (4<sup>th</sup> edition), we aim to provide practical, guideline-based learning that supports everyday clinical practice.

## How to use each module:

Each module follows the flow of one section of the APGG, concluding with a summary to reinforce key learning points

## Look out for:

**Expert tips and tricks – practical insights from the faculty**

*Tips and tricks from the experts*

**FAQs from the APGG – answers to common clinical questions**



*FAQs from the APGG*



# Introduction to **Module 4: Laser and surgical treatment**

**Module 4 focuses on laser and surgical treatment for glaucoma, outlining the indications, techniques, and postoperative considerations for available laser and surgical interventions:**



## Laser treatment

- Laser trabeculoplasty
- Laser peripheral iridotomy
- Peripheral iridoplasty
- Cyclophotocoagulation
- Micropulse laser
- Laser suture lysis



## Surgical treatment

- Trabeculectomy
- Glaucoma drainage devices
- Minimally invasive glaucoma surgery
- Non-penetrating glaucoma surgery
- Phaco-goniosynechialysis

## Meet the expert faculty:

The laser and surgical treatment module was developed with guidance and insights from the following faculty members from the EAGLE Alliance, whose expertise helped shape the content for use in daily practice:

**Assoc. Prof. Visanee Tantisevi**

**Assoc. Prof. Shamira Perera**

**Assoc. Prof. Virna Dwi O. Asrory**



# Laser treatment



# Laser trabeculoplasty



ALT and SLT are the most commonly used lasers for trabeculoplasty.



**Laser trabeculoplasty is a relatively effective and non-invasive procedure that increases TM outflow and allows bypassing of non-adherence to medical therapy<sup>1</sup>**



## Indications

- 1. Medical therapy failure**
- 2. Adjunct to medical therapy**
- 3. Primary treatment, if appropriate**



## ALT and SLT have similar efficacy:<sup>1,2</sup>

- Effective in 80–85% of treated eyes with a mean IOP reduction of 20–25% (6–9 mmHg)
- Effect wears off over time for both ALT and SLT

Variables	SLT	ALT
Number of spots	30–50	50
Exposure time (nanoseconds)	3	100,000,000
Fluence (mJ/mm <sup>2</sup> )	6	40,000
Power	0.4–1.4 mJ	300–600 mW
Laser requirements	Ultrashort pulse duration; low laser energy	

ALT: argon laser trabeculoplasty; IOP: intraocular pressure; SLT: selective laser trabeculoplasty; TM: trabecular meshwork.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. Bovell AM, et al. *Can J Ophthalmol* 2011;46:408–13.



© 2026 Santen Pharmaceutical Asia Pte. Ltd. All rights reserved.



# Selective laser trabeculoplasty



## Pre-laser treatment<sup>1</sup>

- Pre-laser treatment with topical  $\alpha 2$  agonist (or similar) helps reduce post-treatment IOP spikes

## Post-laser management<sup>1,2</sup>

- Give  $\alpha 2$  agonist, recheck IOP at 1 hour
  - **If high IOP:** additional treatment, recheck the next day
  - **If normal IOP:** follow-up at 1 week, 4 weeks, and 3 months
- Post-laser NSAIDs are an option, but not compulsory
- Resume glaucoma eye drops immediately

## Complications<sup>3,4</sup>

- Temporary blurred vision
- IOP spikes with possible VF loss
- Transient iritis
- Chronic increase in IOP
- Corneo-refractive changes
- Suprachoroidal effusion

## Repeat SLT treatment

Initial SLT may not be long-lasting and can be repeated, especially in eyes that have shown a prolonged response to previous treatment<sup>1,2</sup>

**SLT is considered relatively safe to repeat twice<sup>5</sup>**

IOP: intraocular pressure; SLT: selective laser trabeculoplasty; VF: visual field.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. Jorizzo PA, et al. *Am J Ophthalmol* 1988;106:682–5; 3. Kennedy CJ, et al. *Aust N Z J Ophthalmol* 1996;24:279–82; 4. Zhou Y, Aref A. *Ophthalmol Ther* 2017 Mar 3;6:19–32; 5. Lai J. *Invest Ophthalmol Vis Sci* 2005;46:119.



# Laser peripheral iridotomy




**LPI relieves pupillary block via a full-thickness hole created in the peripheral iris**



## Indications

1. Laser treatment to connect the anterior and posterior chambers to relieve pupillary block
2. PAC and PACG: significant pupillary block
3. PACS (absolute): PAC in the fellow eye
4. PACS (relative): need for repeated dilated examinations; poor access to regular ophthalmic care; family history of PACG
5. Secondary angle closure with pupillary block

## Patient examination prior to LPI:





# Steps in laser peripheral iridotomy management



## Pre-laser:<sup>1</sup>

- Instill 2% or 4% pilocarpine
- Consider 1% apraclonidine or 0.15%–0.2% brimonidine, and/or a beta blocker, and/or oral CAI, and/or steroid drops for inflammation
- Topical anaesthesia: Three applications of proparacaine in 5-minute intervals
- Topical glycerine if the cornea is oedematous
- Lenses: Abraham (+66 diopters), Wise (+103 diopters), or CGI©LASAG CH lens (procedure).
- LPI site is usually chosen in the superior quadrants of the iris, well covered by the upper eyelid, in a thin looking area or a small iris crypt
- A temporally placed iridotomy may lead to reduced visual symptoms
- Care should be taken to perform iridotomies peripherally and the laser should not be placed at the junction of eyelid margin to avoid diplopia
- Patients should be warned of the low risk of visual symptoms, which can occur regardless of the site of the iridotomy



## Laser:<sup>1</sup>

Nd:YAG

Argon

“Sequential” laser: argon followed by Nd:YAG

Sequential LPI is useful in eyes with thick irides as well as in patients receiving systemic anticoagulation or antiplatelet medication to reduce the risk of hyphaema



# Parameters of different laser types<sup>1\*</sup>



	Spot size (µm)	Exposure time (s)	Power (mW)
<b>Continuous-wave argon laser</b>			
<b>Preparatory stretch burns</b>	200–500	0.2–0.5	200–600
<b>Penetration laser burns</b>	50	0.05–0.1	700–1000
<b>Parameters according to iris color</b>			
<b><i>Pale blue or hazel irises</i></b>			
1. Obtain a gas bubble	50	0.5	1500
2. Penetration through the gas bubble	50	0.05	1000
<b><i>Thick dark brown irises (chipping technique)<sup>2</sup></i></b>			
Choose/modify parameters depending on individual response	50	0.05–0.1	600–1000
<b>Sequential laser-argon laser followed by Nd:YAG laser (particularly for darker irises)</b>			
<b>Preparatory burns with argon laser (chipping technique)<sup>3</sup></b>			
Depending on iris pigmentation (darker irises require lower power)	50	0.02–0.05	500–1000*
<b>Nd:YAG laser</b>			
Once penetration has occurred, reduce power to continue enlarging the iridotomy horizontally <sup>3†</sup> as lens damage and zonule weakness are possible above 2 mJ per pulse once the iris has been penetrated	–	1–3 pulses per burst	1.5–3 mJ (minimum energy)

\*Further details on pre-operative preparation and post-operative treatment can be found in the APGG, 4<sup>th</sup> edition<sup>1</sup>; † iridotomy size is typically ~2mm to ensure long-term patency.

CPC: cyclophotocoagulation; IOP: intraocular pressure; Nd:YAG: neodymium yttrium aluminum garnet.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. de Silva DJ, et al. *Br J Ophthalmol* 2007;91:222–5;

3. Fleck BW. *Br J Ophthalmol* 1990;74:583–8.



# Peripheral iridoplasty



**Peripheral iridoplasty is a non-invasive laser treatment to flatten the peripheral iris, widen the anterior chamber angle inlet, and re-open appositionally closed segments of the drainage angle<sup>1</sup>**



## Indications

1. Acute angle closure<sup>2-8</sup>
2. Where the angle remains occludable following LPI<sup>9,10</sup>
3. Secondary forms of acute angle closure<sup>11-13</sup>
4. To facilitate access to the TM for laser trabeculoplasty<sup>2</sup>
5. As an adjunct to GSL<sup>14,15</sup>
6. Plateau iris syndrome

### Pre-laser:<sup>1</sup>

Instill 2% or 4% pilocarpine	Use treatment to reduce post-laser IOP spikes/inflammation	Topical anesthesia: three instillations of proparacaine in 5-minute intervals
---------------------------------	--	---



### Post-laser:<sup>1</sup>

If no preventive treatment, check IOP at 1 hour and 24-48 hours	Topical corticosteroids 4-6 times per day for ≥7 days	Repeat gonioscopy to assess angle and other closure mechanisms
---	--	---

GSL: goniosynechialysis; LPI: laser peripheral iridotomy; PAS: peripheral anterior synechiae; TM: trabecular meshwork.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. Lam DS, et al. *Ophthalmology* 1998;105:2231-6; 3. Lai JS, et al. *Eye (Lond)* 1999;13 (Pt 1):26-30; 4. Tham CC, et al. *Ophthalmology* 1999;106:1042-3; 5. Lai JS, et al. *J Glaucoma* 2001;10:89-94; 6. Lai JS, et al. *J Glaucoma* 2002;11:484-7; 7. Lam DS, et al. *Ophthalmology* 2002;109:1591-6; 8. Lai JS, et al. *Eye (Lond)* 2006;20:309-14; 9. Yeung BY, et al. *Clin Exp Ophthalmol* 2005;33:478-82; 10. Ritch R, et al. *Ophthalmology* 2004;111:104-8; 11. Tham CC, et al. *Eye (Lond)* 2005;19:778-83; 12. Yip PP, et al. *Ophthalmic Surg Lasers Imaging* 2005;36:286-91; 13. Thyagarajan S. *Eye (Lond)* 2006;20:1323; author reply 1323-4; 14. Lai JS, et al. *J Glaucoma* 2000;9:388-91; 15. Lai JS, et al. *J Glaucoma* 2001;10:309-15.



**EAGLE**  
ENCOURAGE ADVOCACY  
for GLAUCOMA EDUCATION



**APGS**  
Asia-Pacific Glaucoma Society




# Peripheral iridoplasty



Peripheral iridoplasty is a non-invasive laser treatment to flatten the peripheral iris, widen the anterior chamber angle inlet, and re-open appositionally closed segments of the drainage angle<sup>1</sup>

Variables	Laser parameter <sup>1,2</sup>
Power	150–240 mW depending on the reaction
Spot size	500 µm; both small-spot and large-spot patterns can be used
Exposure time	0.5 second
Number of spots	10–40 applications over 360°, leaving at least 1- to 2-spot diameters between spots; 180° treatment may also be effective <sup>2</sup>

## Complications to look out for:<sup>1</sup>



GSL: goniosynechialysis; LPI: laser peripheral iridotomy; PAS: peripheral anterior synechiae; TM: trabecular meshwork.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. Vera V, et al. *Am J Ophthalmol* 2014;157:929–35.



# Cyclophotocoagulation<sup>1\*</sup>




**CPC, or cyclodiode, is an effective modality for reducing aqueous inflow by coagulative destruction of the ciliary epithelium<sup>1</sup>**



## Indications<sup>1</sup>

1. Painful blind eyes or poor vision
2. Sighted eyes where the benefits and risks of CPC outweigh those for surgery
3. Failed multiple filtering surgeries
4. Primary procedure to alleviate pain in secondary glaucoma with poor visual potential
5. When incisional surgery is not appropriate

## Postoperative management:<sup>1</sup>



\*Further details on pre-operative preparation can be found in the APGG, 4<sup>th</sup> edition<sup>1</sup>  
CPC: cyclophotocoagulation.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024.



# Cyclophotocoagulation



**CPC, or cyclodiode, is an effective modality for reducing aqueous inflow by coagulative destruction of the ciliary epithelium<sup>1</sup>**

Variables	Laser parameter <sup>1</sup>
Wavelength	810 nm
Exposure time	2.0–4.0 seconds
Power	1000–2500 mW
Number of burns	20-40 over 180°–360° (depending on IOP lowering required)
Location	Anterior edge of footplate, alternating 0.0–1.0 mm from the limbus to cover the full width of the ciliary body. Avoid the 3 and 9 o'clock positions due to the long ciliary nerves and vessels

## Complications to look out for:

- Pain
- Persistent inflammation
- Loss of visual acuity<sup>2,3</sup>
- Hypotony<sup>4</sup>
- Phthisis<sup>5</sup>
- Scleral thinning or rupture<sup>6-8</sup>
- Pupillary distortion<sup>9</sup>
- Macular edema
- Retinal detachment<sup>10</sup>
- Aqueous misdirection syndrome<sup>5</sup>
- Sympathetic ophthalmia<sup>11</sup>

**The laser tip should be placed over the ciliary body, i.e., the dark band posterior to the perilimbal halo seen with transillumination<sup>1</sup>**

CPC: cyclophotocoagulation.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. Schuman J, et al. *Ophthalmol* 1992;99:1089–94; 3. Shields M, Shields S. *Trans Am Ophthalmol Soc* 1994;92:271-283; 4. Maus M, Katz L. *Ophthalmology* 1990;97:69-72; 5. Trope G, Ma S. *Ophthalmology* 1990;97:73-75; 6. Bhola R, et al. *Eye (Lond)* 2001;15:453-457; 7. Fiore P, et al. *Ophthalmic Surg* 1989;20:215-16; 8. Kwong Y, et al. *Eye (Lond)* 2006;20:1316-17; 9. Lai J, et al. *Eye (Lond)* 2002;16:674-75; 10. Geyer O, et al. *Ann Ophthalmol* 1993;25:170-72; 11. Lam S, et al. *Ophthalmology* 1992;99:1818-22.



**EAGLE**  
ENCOURAGE ADVOCACY  
for GLAUCOMA EDUCATION



**APGS**  
Asia-Pacific Glaucoma Society



# Micropulse laser



Micropulse laser is **another modality for CPC**, but with the potential advantage of a more homogeneous distribution of energy resulting in less energy use and a lower rate of complications. It can be titrated if further IOP-lowering is required and repeated if there is loss of IOP-lowering efficacy

- Slit-lamp to select site; stop anticoagulants if possible
- Anesthetic block ( $\pm$  sedation) over topical anesthesia alone
- Use coupling gel; probe sweeps across hemisphere
- Avoid 3 and 9 o'clock positions
- Less pain than cyclodiode
- Continue any current glaucoma treatment
- Optimal IOP lowering seen at 1 month
- Adjust drops based on response
- Follow-up: 1 week, then 1 month
- Topical steroids/NSAIDs used for 1–4 weeks

## Pre-laser

## Laser

## Post-laser





# Laser suture lysis



**Laser suture lysis is an effective, non-invasive postoperative laser treatment for IOP titration after filtering surgery**



**Indication:** commonly within 7–28 days of glaucoma filtering surgery



## Key steps in management:


**Pre-laser:** topical anesthesia

**Laser types:** argon, diode, Nd:YAG

**Lenses:** Ritch, Hoskins, Mandelkorn, Zeiss, glass rod

**Technique:** cut one suture per session; adjust if blood present

## Complications to look out for:





# Laser power by type



A useful tip to reduce laser power for laser iridotomy is to choose a small iris crypt or thin iris area that is located peripherally as possible.



Laser type	Power
Laser trabeculoplasty	300–1200 mW, depending on the tissue reaction
SLT	0.4–1.4 mJ
ALT	300–600 mW
LPI	Set at 1.5–3 mJ, depending on thickness of the iris
Continuous-wave argon laser	<ul style="list-style-type: none"><li>• Preparatory stretch burns: 200–600 mW</li><li>• Penetration laser burns: 700–1000 mW</li><li>• Pale blue or hazel irises:<ul style="list-style-type: none"><li>○ Obtain a gas bubble: 1500 mW</li><li>○ Penetrate through the gas bubble: 1000 mW</li></ul></li><li>• Thick dark brown irises: 600–1000 mW</li></ul>
Sequential laser–argon laser followed by ND:YAG laser	500–1000 mW, depending on iris pigmentation
Peripheral iridoplasty	150–240 mW, depending on the reaction
Cyclophotocoagulation	1000–2500 mW
Micropulse laser	1600–2500 mW
Laser suture lysis	300–800 mW
Laser goniopuncture	3–6 mJ, starting at 3 mJ



# Surgical treatment



# Trabeculectomy



Trabeculectomy is the most performed glaucoma filtering surgery and is conventionally considered the gold standard of penetrating surgery to create a subconjunctival bleb without the need for an implant<sup>1</sup>



## Indications<sup>1</sup>

1. Glaucoma status (e.g. moderate to severe) requiring a low target IOP that is unlikely to be achieved with medication or laser
2. Where other therapies are inappropriate (e.g. poor adherence, side effects, socioeconomic problems)
3. Failed medical and/or laser treatment

## Preoperative assessment<sup>1,2</sup>



Evaluate visual acuity and estimate the predicted visual outcome



Evaluate the conjunctival health of the selected location for the filtering bleb, as well as its mobility and adhesion



Identify risk factors for treatment failure

IOP: intraocular pressure.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. Allingham RR. Shields' Textbook of Glaucoma: Lippincott Williams & Wilkins; 2005.



# Trabeculectomy: surgical technique




**10. Postsurgery modulation:** anti-inflammatories (NSAIDs, steroids), laser suture lysis/releasable sutures, optional collagen matrix implant

**9. Closure:** meticulous Tenon's and conjunctiva closure to prevent leaks

**8. Scleral flap suturing:** 10-0 nylon (fixed or releasable), titrate filtration, reduce hypotony

**7. Fistulizing technique:** blade and punch, or micro-drainage device

**6. Scleral flap:** triangular, semicircular, or trapezoidal



**1. Anesthesia:** topical, sub-Tenon's, or peribulbar

**2. Corneal traction suture:** 8-0 suture to rotate globe and expose conjunctiva

**3. Conjunctival flap:** fornix- or limbus-based (similar success)

**4. Undermine conjunctiva:** blunt scissors to avoid tear

**5. Antimetabolite application:** sponge or injection to reduce bleb failure

NASID: nonsteroidal anti-inflammatory drug.

1. Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines. 4th ed. May 2024; 2. Al-Haddad CE, et al. *Am J Ophthalmol* 2017;174:33–41; 3. Clemente P. *Klin Monbl Augenheilkd* 1980;177:455–8; 4. Dellaporta A. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol* 1975;79:OP362–71; 5. He M, et al. *PLoS One* 2014;9:e85782.



© 2026 Santen Pharmaceutical Asia Pte. Ltd. All rights reserved.



# Postoperative management of trabeculectomy




The first **12 postoperative weeks are critical** for trabeculectomy outcomes, and intensive individualized care must be provided




**1st or 2nd postoperative day**  
Examine the patient and then as clinically indicated.  
Intensive topical steroids.



**2-6 weeks**  
Consider cycloplegics, especially for those at risk of ciliary block.  
Intensive topical steroids.



**First 8-12 weeks**  
Prescribe intensive topical steroids (starting at 2-3 hourly and gradually tapering off depending on clinical findings)  
Prescribe topical antibiotics until the topical steroid frequency is reduced to 2-3 times daily




**Up to 4-5 months postoperatively**  
Steroids may need to be continued for patients at persistent risk of scar formation

**From 1-4 weeks consider laser suture lysis**



# Post-trabeculectomy complications



IOP: intraocular pressure.

Oktariana V. Oral presentation, presented at Sumatera Ophthalmologist Meeting, March 2-4 2023, Bukittinggi, West Sumatera, Indonesia.



# Use of adjunctive agents in glaucoma surgery



**Antimetabolite agents (MMC and 5-FU) have been shown to inhibit scarring, which is a major cause of failure following filtration surgery<sup>1</sup>**



## Indications<sup>2</sup>

Adjunctive agents are the current gold standard intraoperative treatment for bleb-forming surgeries, including in:

- Repeat surgery
- Neovascular glaucoma
- Uveitic glaucoma
- Aphakic glaucoma
- Younger patients
- Populations of African descent

## Antimetabolites



**MMC:** used widely in filtering surgery<sup>2</sup>

**5-FU:** used less with filtering surgery due to reduced efficacy compared with MMC. More commonly used postoperatively, combined with needling<sup>2</sup>



**Antimetabolites can result in complications; caution and monitoring are mandatory. They are contraindicated in pregnancy and lactation<sup>3</sup>**

5-FU: 5-fluorouracil; MMC: mitomycin C.

1. Khaw PT. *J Glaucoma* 2001;10(5 Suppl 1):S81–4; 2. Asia-Pacific Glaucoma Society (APGS). *Asia-Pacific Glaucoma Guidelines*. 4th ed. May 2024;

3. Lin ZJ, et al. *J Ocul Pharmacol Ther* 2012;28:166–73.



# Glaucoma drainage devices: Valved versus non-valved



**GDDs are implants consisting of a tube connected to a reservoir plate that diverts aqueous from the anterior chamber to a reservoir placed in the equator, where fluid is absorbed by surrounding vessels to lower IOP**

## Valved

May have a lower rate of immediate hypotony, but postoperative hypotony can occur via peritubular leak

## Non-valved

Greater IOP reduction and lower rates of re-operation, but associated with a greater risk of postoperative hypotony compared with valved

- Previous failed trabeculectomy with antimetabolites
- Insufficient conjunctiva due to scarring
- Complicated and refractory glaucoma



# Glaucoma drainage devices: Valved versus non-valved



**GDDs are implants consisting of a tube connected to a reservoir plate that diverts aqueous from the anterior chamber to a reservoir placed in the equator, where fluid is absorbed by surrounding vessels to lower IOP**

## Valved

- Ahmed Glaucoma Valve (New World Medical, Rancho Cucamonga, CA, USA).
- The possibility of developing an encysted bleb is much higher with the Ahmed implant and the hypertensive phase is more significant.

## Non-valved

- Baerveldt Glaucoma Implant (Johnson and Johnson Vision, Irvine, CA, USA).
- Aravind Aqueous Drainage Implant (Aurolab, Madurai, India).
- Ahmed ClearPath (New World Medical, Rancho Cucamonga, CA, USA).
- Paul Glaucoma Implant (Advanced Ophthalmic Innovations, Singapore).



## Indications

- Previous failed trabeculectomy with antimetabolites
- Insufficient conjunctiva due to scarring
- Complicated and refractory glaucoma



# Glaucoma drainage devices: Surgical technique




**1. Anesthesia:** deep sub-Tenon's, peribulbar , or retrobulbar

**6. Suturing and closure:** patch graft (corneal/scleral/other) to prevent erosion; close conjunctiva with 10-0 nylon or 8-0 Vicryl

**5. Scleral tunnel and tube placement:** create tunnel into AC or sulcus and trim tube length appropriately

- **Anterior chamber:** bevel up on iris surface
- **Sulcus:** bevel down to avoid iris suction
- **Needle size:** 25 or 23 gauge

**4. Plate insertion:** irrigation through the tube prior to insertion (**valved**); aqueous flow restriction (**non-valved**)



**2. Corneal traction suture:** expose upper conjunctiva and inter-rectus sclera

**3. Subconjunctival space:** created with or without radial relaxing incision



# Minimally invasive glaucoma surgery



**MIGS initially referred to ab-interno devices and procedures usually targeting Schlemm's canal. However, the term has broadened to include ab-externo bleb-forming procedures with little or no scleral dissection**

	<b>Class of MIGS</b>	<b>Clinical examples</b>	<b>Key details</b>
	<b>TM MIGS</b>	<b>Stents</b> <b>Ab-interno dilating ± excision</b> <b>Tissue excision MIGS</b>	<b>Indicated in stable and well-controlled mild-to-moderate OAG and OHT, and patients on one to three ocular hypotensive medications</b>
	<b>Subconjunctival MIGS devices</b>	<b>PRESEFLO MicroShunt</b> <b>Xen Gel Stent</b>	<b>Although similar to trabeculectomy, PRESEFLO results in less tissue manipulation at the time of surgery. The Xen decreases IOP by creating a permanent drainage shunt from the AC to the subconjunctival space through a scleral channel</b>
	<b>Suprachoroidal MIGS devices</b>	<b>MINIject glaucoma drainage device</b>	<b>A supraciliary, minimally invasive, soft, flexible silicone implant that drains into the suprachoroidal space</b>



# Minimally invasive glaucoma surgery



## TM MIGS

## Subconjunctival MIGS devices

## Suprachoroidal MIGS devices

### STENT PROCEDURES

- **Ab-interno dilating ± excision**
  - iTrack Advance Microcatheter (Ellex, Adelaide, Australia)
  - OMNI Surgical System (Menlo Park, CA, USA)
- **Tissue excision MIGS**
  - Kahook Dual Blade (New World Medical, Rancho Cucamonga, CA, USA)
  - Tanito Microhook (Inami, Tokyo, Japan)
  - Trabectome (NeoMedix Corporation, Tustin, CA USA)
  - Gonioscopy-assisted transluminal trabeculotomy

### PRESERFLO MICROSHUNT

- A stent made of SIBS (poly[styrene-block-isobutylene-block-styrene]) material
- Dimensions: 8.5 mm in length, with a 1 mm fin (external diameter: 350 µm; internal lumen: 70 µm)
- Keep ocular pressure high with reinflation to ensure immediate flow through the PRESERFLO upon insertion

### XEN GEL STENT

- Made of porcine collagen-derived gelatine
- Dimensions: 6 mm hydrophilic flexible tube with a 45 µm lumen
- Decreases intraocular pressure by creating a permanent drainage shunt from the anterior chamber to the subconjunctival space through a scleral channel

### MINIject GLAUCOMA DRAINAGE DEVICE

- Supraciliary, minimally invasive, soft, flexible silicone implant that drains into the suprachoroidal space
- Dimensions: 1.1×0.6×5 mm in length
- Can be inserted ab-interno into the suprachoroidal space as a stand-alone procedure



# Non-penetrating glaucoma surgery




**NPGS is a form of drainage surgery where Schlemm's canal is de-roofed underneath a scleral flap and deep corneoscleral lamellae are removed to create an intrascleral lake**



## Indications

- Failed medical and/or laser treatment, where there is still a need for a lower target IOP in eyes with an open and normal angle
- In higher-risk patients, it may reduce the hypotony risks of trabeculectomy

## Key points for NPGS



**Reduces IOP less effectively than penetrating surgery, but has lower complication rates**



**Requires a steep learning curve**



**The deep sclerectomy may be performed manually or assisted with CO<sub>2</sub> laser**



# Phaco-goniosynechialysis



**GSL involves separation of the PAS with a spatula, micro forceps, or needle under gonioscopic guidance, and is often used with phacoemulsification (i.e. phaco-GSL) to open the angle**

## Tips

- Proficiency with gonioscopy is imperative
- Miotics may help, and some surgeons perform argon laser iridoplasty to maintain the angle opening
- Diamox is useful postoperatively to prevent IOP spikes

## Contra-indications

- Traumatic, malignant, uveitic, or neovascular glaucoma
- Discernible congenital anomalies of the anterior chamber angle
- Cases where PAS is known to be longstanding are less likely to be successful



## When to use

- Phaco-GSL is a good option to treat PACG with concomitant cataract due to its bleb-less nature
- Capacity for lowering IOP seems superior to that of phacoemulsification alone
- Phaco-GSL is an option when lens extraction is performed after an acute angle-closure attack



# Identifying patients who may benefit from alternatives to eye drops



## Who might benefit from first-line laser?

- **OHT or early POAG with presumed intolerance to eye drops**
- **Younger age**
- **Active lifestyle (lots of outdoors activities, frequent travellers)**
- **Easily lost to follow-up**
- **Any age group reporting frequent forgetfulness**




## Who might benefit from surgery?

- **Patients with moderate to advanced glaucoma who cannot tolerate eye drops**
- **A discussion is needed to determine the appropriate surgical approach: MIGS, MIBS, trabeculectomy, or GDD**

**Surgical choice is guided by the target IOP intended to be achieved with the procedure.**



# Identifying patients who may benefit from alternatives to eye drops





# Summary: When to use different laser treatments



## OAG

- **Outflow enhancement:**  
laser trabeculoplasty
- **Inflow reduction:**  
CPC (usually for end-stage disease)

## Angle closure (± glaucoma)

- **Pupillary block relief:**  
laser peripheral iridotomy
- **Modification of iris contour:**  
laser peripheral iridoplasty
- **Inflow reduction:**  
CPC (usually for end-stage disease)

## Post-filtering surgery

- **Outflow enhancement:**  
argon laser suture lysis



# Summary: Surgical approaches for glaucoma



**1** Trabeculectomy is the most performed glaucoma filtering surgery and is conventionally considered the gold standard of penetrating surgery to create a subconjunctival bleb without the need for an implant

**2** GDDs are implants consisting of a tube connected to a reservoir plate that diverts aqueous from the anterior chamber to a subconjunctival bleb, where fluid is absorbed by surrounding vessels to lower IOP

**3** MIGS initially referred to ab-interno devices and procedures usually targeting Schlemm's canal. However, the term has broadened to include ab-externo bleb-forming procedures with little or no scleral dissection

**4** NPGS is a form of drainage surgery where Schlemm's canal is de-roofed underneath a scleral flap and deep corneoscleral lamellae are removed to create an intrascleral lake

**5** GSL involves separation of the PAS with a spatula, micro forceps, or needle under gonioscopic guidance and is often used with phacoemulsification to open the angle